Clinical study of ulinastatin on the treatment of systemic inflammatory response syndrome in severe acute pancreatitis
10.3760/cma.j.issn.1673-4904.2009.04.011
- VernacularTitle:乌司他丁治疗重症急性胰腺炎系统性炎症反应综合征的临床研究
- Author:
Zhijun ZHU
;
Weixing YOU
;
Yi CHEN
- Publication Type:Journal Article
- Keywords:
Pancreatitis,acute necrotizing;
Systemic inflammatory response syndrome;
Ulinas-tatin
- From:
Chinese Journal of Postgraduates of Medicine
2009;32(4):29-31
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical value of ulinastatin on the treatment of systemic inflammatory response syndrome in severe acute panereatitis. Method Eighty-four patients with severe a-cute pancreatitis were randomly divided into two groups. In the treatment group (42 cases),on the base of routine treatment, ulinastatin was administered intravenously for seven days after hospitalization, while in the control group only routine treatment was given (42 cases) to. Inflammatory factors in serum, the change of liver function and renal function were measured in two groups before and after the treatment, and the clinical efficacy were observed. Results There was significant difference, in the serum level of tumor necrosis factor-α, interleukin-1, interleukin-6, alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen and creatinine on the 7th day between two groups (P < 0.05 or < 0.01 ) ,there were significant differences in the incidence of complications, hospitalization time, incidence of multi-organ failure between two groups [14.3%(6/42) vs 38.1%(16/42), (29.4 ± 1.5)d vs (34.4 ± 1.8)d, 28.6%(12/42) vs 47.6%(20/42), P<0.01 or <0.05 ]. Conclusions Ulinastatin can suppress the secretion and release of some inflammatory factors, protect the important viscera functions and reduce the incidence of complications, and it has favorable clinical efficacy.
